CN108700596A - 用于心血管疾病和事件的诊断和预后方法 - Google Patents

用于心血管疾病和事件的诊断和预后方法 Download PDF

Info

Publication number
CN108700596A
CN108700596A CN201780011650.8A CN201780011650A CN108700596A CN 108700596 A CN108700596 A CN 108700596A CN 201780011650 A CN201780011650 A CN 201780011650A CN 108700596 A CN108700596 A CN 108700596A
Authority
CN
China
Prior art keywords
biomarkers
history
sample
group
prognosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780011650.8A
Other languages
English (en)
Chinese (zh)
Inventor
朗达·费伊·瑞恩
克雷格·阿伽门农·玛格丽特
约翰·爱德华·斯特罗贝克
小詹姆士·路易斯·贾努齐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prevencio Inc
Original Assignee
Prevencio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prevencio Inc filed Critical Prevencio Inc
Priority to CN202210116587.7A priority Critical patent/CN114441773A/zh
Publication of CN108700596A publication Critical patent/CN108700596A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4884—Other medical applications inducing physiological or psychological stress, e.g. applications for stress testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/503—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the heart
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
CN201780011650.8A 2016-02-01 2017-02-01 用于心血管疾病和事件的诊断和预后方法 Pending CN108700596A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210116587.7A CN114441773A (zh) 2016-02-01 2017-02-01 用于心血管疾病和事件的诊断和预后方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662289513P 2016-02-01 2016-02-01
US62/289,513 2016-02-01
US201662378535P 2016-08-23 2016-08-23
US62/378,535 2016-08-23
PCT/US2017/016081 WO2017136464A1 (en) 2016-02-01 2017-02-01 Diagnostic and prognostic methods for cardiovascular diseases and events

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210116587.7A Division CN114441773A (zh) 2016-02-01 2017-02-01 用于心血管疾病和事件的诊断和预后方法

Publications (1)

Publication Number Publication Date
CN108700596A true CN108700596A (zh) 2018-10-23

Family

ID=59500904

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780011650.8A Pending CN108700596A (zh) 2016-02-01 2017-02-01 用于心血管疾病和事件的诊断和预后方法
CN202210116587.7A Pending CN114441773A (zh) 2016-02-01 2017-02-01 用于心血管疾病和事件的诊断和预后方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210116587.7A Pending CN114441773A (zh) 2016-02-01 2017-02-01 用于心血管疾病和事件的诊断和预后方法

Country Status (13)

Country Link
US (4) US10983135B2 (enExample)
EP (2) EP4574024A3 (enExample)
JP (4) JP7134870B2 (enExample)
KR (1) KR20180101595A (enExample)
CN (2) CN108700596A (enExample)
AU (1) AU2017214469A1 (enExample)
BR (1) BR112018015698A2 (enExample)
CA (1) CA3012192A1 (enExample)
MA (1) MA43980A (enExample)
MX (1) MX2018009304A (enExample)
RU (1) RU2018130866A (enExample)
SG (1) SG11201805906WA (enExample)
WO (1) WO2017136464A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110232975A (zh) * 2019-05-20 2019-09-13 郑州大学第一附属医院 一种对糖尿病肾病患者3年内进入到肾脏替代治疗风险预测的方法
CN110491512A (zh) * 2019-08-08 2019-11-22 郑州大学第一附属医院 一种对肾活检确诊糖尿病肾病患者3年内进入到终末期肾脏病风险预测的方法
CN110596399A (zh) * 2019-08-29 2019-12-20 首都医科大学附属北京安贞医院 检测血管生成素样蛋白8含量的物质的应用
CN110970131A (zh) * 2019-10-24 2020-04-07 中国医科大学附属盛京医院 一种基于免疫球蛋白定量检测的肾小球疾病分类分型模型及其应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108700596A (zh) 2016-02-01 2018-10-23 普雷西奥公司 用于心血管疾病和事件的诊断和预后方法
EP3682240B1 (en) * 2017-09-14 2024-01-24 Laboratory Corporation of America Holdings Assessing myocardial infarction and serious infection risk in rheumatoid arthritis patients
CA3081752A1 (en) * 2017-11-02 2019-05-09 Prevencio, Inc. Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes
US11009452B2 (en) * 2018-01-26 2021-05-18 Viavi Solutions Inc. Reduced false positive identification for spectroscopic quantification
ES3017793T3 (en) * 2019-02-20 2025-05-13 Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol In vitro method for predicting mortality risk in patients suffering from cardiogenic shock
RU2726314C1 (ru) * 2019-11-15 2020-07-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ раннего прогнозирования риска острого повреждения почек у пациентов с ишемической болезнью сердца после реваскуляризации миокарда методом аортокоронарного шунтирования
RU2760445C1 (ru) * 2020-11-13 2021-11-25 Виталий Юрьевич Мишланов Способ диагностики патологических состояний человека
WO2022202360A1 (ja) * 2021-03-23 2022-09-29 テルモ株式会社 情報処理装置、情報処理方法およびプログラム
CN113342963B (zh) * 2021-04-29 2022-03-04 山东大学 一种基于迁移学习的服务推荐方法及系统
RU2770550C1 (ru) * 2021-05-31 2022-04-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ прогнозирования сердечно-сосудистого риска с помощью определения уровня эстрогенов
EP4500552A2 (en) * 2022-03-30 2025-02-05 Inflammatix, Inc. Methods for diagnosing myocardial infarction
CN114974576A (zh) * 2022-07-12 2022-08-30 曜立科技(北京)有限公司 一种基于元数据的心脑血管数疾病诊断管理系统
CN115185936B (zh) 2022-07-12 2023-02-03 曜立科技(北京)有限公司 一种基于大数据的医疗临床数据质量分析系统

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146229A2 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
WO2008131039A2 (en) * 2007-04-16 2008-10-30 Board Of Regents, The University Of Texas System Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics
CN101454024A (zh) * 2005-12-07 2009-06-10 西门子医疗保健诊断公司 可溶性脂连蛋白受体肽的检测以及在诊断和治疗中的用途
CN101495862A (zh) * 2005-06-24 2009-07-29 利兰·斯坦福青年大学托管委员会 诊断和监测动脉粥样硬化性心血管疾病的方法和组合物
WO2010144358A1 (en) * 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
WO2011022628A1 (en) * 2009-08-20 2011-02-24 The Board Of Regents Of The University Of Texas System Methods and compositions for diagnosis of acute myocardial infarction (ami)
US20110144914A1 (en) * 2009-12-09 2011-06-16 Doug Harrington Biomarker assay for diagnosis and classification of cardiovascular disease
KR20110085436A (ko) * 2010-01-20 2011-07-27 연세대학교 산학협력단 비만 또는 당뇨에 관련된 단일염기다형성 및 그의 용도
US8241861B1 (en) * 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
WO2014078615A1 (en) * 2012-11-16 2014-05-22 Siemens Healthcare Diagnostics Inc. Method to identify optimum coronary artery disease treatment
WO2015171989A1 (en) * 2014-05-08 2015-11-12 University Of Maryland, Baltimore Methods for assessing differential risk for developing heart failure

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20080202927A1 (en) 2000-11-03 2008-08-28 Clinical Micro Sensors, Inc. Devices and methods for biochip multiplexing
US20030134433A1 (en) 2002-01-16 2003-07-17 Nanomix, Inc. Electronic sensing of chemical and biological agents using functionalized nanostructures
US20060228723A1 (en) 2002-01-16 2006-10-12 Keith Bradley System and method for electronic sensing of biomolecules
US9234867B2 (en) 2003-05-16 2016-01-12 Nanomix, Inc. Electrochemical nanosensors for biomolecule detection
US8685711B2 (en) 2004-09-28 2014-04-01 Singulex, Inc. Methods and compositions for highly sensitive detection of molecules
US20080269346A1 (en) * 2005-02-17 2008-10-30 University Of Florida Research Foundation, Inc. B-Blocker Pharmacogenetics in Heart Failure
US20100331200A1 (en) * 2006-03-31 2010-12-30 Gordon Neal F Post translational modification pattern analysis
WO2008045799A2 (en) 2006-10-06 2008-04-17 Nanomix, Inc. Electrochemical nanosensors for biomolecule detection
PL2084543T3 (pl) * 2006-10-26 2018-04-30 B.R.A.H.M.S Gmbh Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II
US20100119600A1 (en) 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
GB0717637D0 (en) 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
US20100267062A1 (en) * 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
RU2568354C2 (ru) 2009-06-04 2015-11-20 Конинклейке Филипс Электроникс, Н.В. Способ и система обеспечения поведенческой терапии для лечения бессонницы
WO2012072595A1 (en) * 2010-11-30 2012-06-07 Universiteit Gent Platelet factor 4 variant for the prognosis of cardiovascular outcome in patients having heart disease
BR112013022952B1 (pt) 2011-03-09 2020-09-08 Abionic Sa Biossensor, matriz compreendendo diversos biossensores, montagem consistindo em um ou diversos biossensores e método para detectar e quantificar a presença de biomoléculas
US20140193846A1 (en) * 2011-04-19 2014-07-10 Scott & White Healthcare Novel apoc-i isoforms and their use as biomarkers and risk factors of atherosclerotic disease
US20140011811A1 (en) * 2011-10-06 2014-01-09 The United States Government As Represented By The Department Of Veterans Affairs Myosin binding protein-c for use in methods relating to diastolic heart failure
CA2953789A1 (en) 2013-07-12 2015-01-15 Emory University Diagnostic assay to predict cardiovascular risk
EP3021968B1 (en) 2013-07-17 2018-09-26 Abionic SA Method and device for bioassays
WO2015085314A2 (en) * 2013-12-06 2015-06-11 Diadexus, Inc. Methods for detection of heart failure
ES2973772T3 (es) 2014-07-03 2024-06-24 Abionic Sa Cápsula de cuantificación molecular rápida de una muestra de fluido, tal como sangre completa
CN108700596A (zh) 2016-02-01 2018-10-23 普雷西奥公司 用于心血管疾病和事件的诊断和预后方法
JP7310591B2 (ja) 2019-12-19 2023-07-19 株式会社オートネットワーク技術研究所 駆動装置

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101495862A (zh) * 2005-06-24 2009-07-29 利兰·斯坦福青年大学托管委员会 诊断和监测动脉粥样硬化性心血管疾病的方法和组合物
CN101454024A (zh) * 2005-12-07 2009-06-10 西门子医疗保健诊断公司 可溶性脂连蛋白受体肽的检测以及在诊断和治疗中的用途
WO2007146229A2 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
WO2008131039A2 (en) * 2007-04-16 2008-10-30 Board Of Regents, The University Of Texas System Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics
US20080300798A1 (en) * 2007-04-16 2008-12-04 Mcdevitt John T Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics
US8241861B1 (en) * 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
WO2010144358A1 (en) * 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
WO2011022628A1 (en) * 2009-08-20 2011-02-24 The Board Of Regents Of The University Of Texas System Methods and compositions for diagnosis of acute myocardial infarction (ami)
US20110144914A1 (en) * 2009-12-09 2011-06-16 Doug Harrington Biomarker assay for diagnosis and classification of cardiovascular disease
CN102762743A (zh) * 2009-12-09 2012-10-31 阿维埃尔公司 用于心血管疾病的诊断和分类的生物标记物检验
KR20110085436A (ko) * 2010-01-20 2011-07-27 연세대학교 산학협력단 비만 또는 당뇨에 관련된 단일염기다형성 및 그의 용도
WO2014078615A1 (en) * 2012-11-16 2014-05-22 Siemens Healthcare Diagnostics Inc. Method to identify optimum coronary artery disease treatment
WO2015171989A1 (en) * 2014-05-08 2015-11-12 University Of Maryland, Baltimore Methods for assessing differential risk for developing heart failure

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
AKANSHA GUPTA等: "Clinical assessment of cardiovascular disorders by cardiac biomarkers", 《INT. J. PHARM. SCI. REV. RES.》 *
AYMAN AL HAJ ZEN等: "Decorin overexpression reduces atherosclerosis development in apolipoprotein E-deficient mice", 《ATHEROSCLEROSIS》 *
K. K. BERG等: "The Additive Contribution From Inflammatory Genetic Markers on the Severity of Cardiovascular Disease", 《CLINICAL IMMUNOLOGY》 *
ROLAND R.J. VAN KIMMENADE等: "Emerging biomarkers in heart failure", 《CLINICAL CHEMISTRY》 *
TODD H. DRIVER等: "Urinary Kidney Injury Molecule 1 (KIM-1) and Interleukin 18 (IL-18) as Risk Markers for Heart Failure in Older Adults The Health, Aging, and Body Composition (Health ABC) Study", 《AM J KIDNEY DIS》 *
TOMÁŠ VAISAR等: "HDL in humans with cardiovascular disease exhibits a proteomic signature", 《CLINICA CHIMICA ACTA》 *
WILLIBALD HOCHHOLZER等: "Novel Biomarkers in Cardiovascular Disease: Update 2010", 《AM HEART J》 *
丁法明等: "基质金属蛋白酶-9和白介素-18在冠心病及糖尿病大血管并发症中的作用", 《西安交通大学学报（医学版）》 *
严轶文等: "急性心肌梗死患者外周血干细胞及干细胞因子的变化", 《中华老年心脑血管病杂志》 *
刘岩等: "低脂联素血症是冠状动脉粥样硬化严重程度的重要标志", 《中华内分泌代谢杂志》 *
尹榕等: "富含亮氨酸低分子蛋白聚糖家族成员Decorin与动脉粥样硬化关系的研究进展", 《中国脑血管病杂志》 *
张小蓬等: "冠状动脉性心脏病各临床表型血清脂连蛋白的测定", 《临床检验杂志》 *
张放鸣等: "动脉粥样硬化血管平滑肌细胞中干细胞因子mRNA的表达水平增加", 《高血压杂志》 *
李宇等: "冠状动脉粥样硬化斑块与MMP2、MMP9水平的关系", 《海南医学院学报》 *
李庆华等: "急性冠状动脉综合征患者血清可溶性E选择素与白介素-8水平", 《中华临床医师杂志（电子版）》 *
杨方等: "人冠状动脉几种细胞外基质的动态变化与动脉粥样硬化形成的关系", 《中华病理学杂志》 *
杨翔等: "血清中期因子midkine与冠心病及其危险因素的相关性分析", 《中华心血管病杂志》 *
王依屹等: "缺血修饰白蛋白、肌钙蛋白、肌红蛋白、肌酸激酶同工酶检测在急性冠状动脉综合征早期发现中的应用", 《标记免疫分析与临床》 *
肖宪杰等: "冠状动脉粥样硬化性心脏病患者血清MMP-2、9及IL-6水平及意义", 《中国老年学杂志》 *
邴秀娟等: "慢性牙周炎合并冠心病患者龈沟液及血清IL-8、IL-10的含量及意义", 《上海口腔医学》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110232975A (zh) * 2019-05-20 2019-09-13 郑州大学第一附属医院 一种对糖尿病肾病患者3年内进入到肾脏替代治疗风险预测的方法
CN110491512A (zh) * 2019-08-08 2019-11-22 郑州大学第一附属医院 一种对肾活检确诊糖尿病肾病患者3年内进入到终末期肾脏病风险预测的方法
CN110596399A (zh) * 2019-08-29 2019-12-20 首都医科大学附属北京安贞医院 检测血管生成素样蛋白8含量的物质的应用
CN110596399B (zh) * 2019-08-29 2022-07-22 首都医科大学附属北京安贞医院 检测血管生成素样蛋白8含量的物质的应用
CN110970131A (zh) * 2019-10-24 2020-04-07 中国医科大学附属盛京医院 一种基于免疫球蛋白定量检测的肾小球疾病分类分型模型及其应用
CN110970131B (zh) * 2019-10-24 2024-01-26 中国医科大学附属盛京医院 一种基于免疫球蛋白定量检测的肾小球疾病分类分型模型及其应用

Also Published As

Publication number Publication date
US11977083B2 (en) 2024-05-07
EP4574024A2 (en) 2025-06-25
US20250060374A1 (en) 2025-02-20
WO2017136464A1 (en) 2017-08-10
EP4574024A3 (en) 2025-10-08
US12146888B2 (en) 2024-11-19
US20210072260A1 (en) 2021-03-11
EP3411720B1 (en) 2025-04-16
EP3411720A4 (en) 2019-08-14
EP3411720A1 (en) 2018-12-12
US20230341418A1 (en) 2023-10-26
BR112018015698A2 (pt) 2018-12-26
CA3012192A1 (en) 2017-08-10
CN114441773A (zh) 2022-05-06
JP2019507354A (ja) 2019-03-14
JP7403498B2 (ja) 2023-12-22
EP3411720C0 (en) 2025-04-16
RU2018130866A (ru) 2020-03-04
JP2022171936A (ja) 2022-11-11
KR20180101595A (ko) 2018-09-12
SG11201805906WA (en) 2018-08-30
JP7134870B2 (ja) 2022-09-12
JP2025029196A (ja) 2025-03-05
US20190369120A1 (en) 2019-12-05
JP2021128177A (ja) 2021-09-02
AU2017214469A1 (en) 2018-07-26
US10983135B2 (en) 2021-04-20
MA43980A (fr) 2018-12-12
MX2018009304A (es) 2019-01-10

Similar Documents

Publication Publication Date Title
US12146888B2 (en) Diagnostic methods for cardiovascular diseases
EP2796878A1 (en) New biomarkers for diagnosis, prediction and/or prognosis of sepsis and uses thereof
US11041867B2 (en) ProADM and/or histones as markers indicating an adverse event
JP7104689B2 (ja) 有害事象を示すマーカーとしてのヒストンおよび／またはｐｒｏＡＤＭ
EP3497450B1 (en) Histones and/or proadm as markers indicating organ dysfunction
CN111065922A (zh) 肾上腺髓质素原作为危重病患者的肾脏替代治疗的指标
HK40074056A (en) Diagnostic and prognostic methods for cardiovascular diseases and events
HK1261993A1 (en) Diagnostic and prognostic methods for cardiovascular diseases and events
HK1261993B (en) Diagnostic and prognostic methods for cardiovascular diseases and events
EP3502691A1 (en) Proadrenomedullin as indicator for renal replacement therapy in critically ill patients
CA3033102C (en) Histones and/or proadm as markers indicating organ dysfunction
Linssen EDUW 2–SYSMEX–Monday 12 June, 14.30-15.30
HK40029189A (en) Proadrenomedullin as indicator for renal replacement therapy in critically ill patients

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181023